However, immunohistochemistry analysis of tumor cells with specific antibodies for IL-6 and VEGF revealed few positive immunostainings of these two targets (Fig. S4 and Table S4), and there were no statistical differences between the two groups, untreated tumors and AM11095 treated tumors. This evidence concerns the gene VEGFA and neoplasm.